AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NeuroPace (NPCE) delivered mixed results in Q3 2025, , . The company narrowed its net loss to $3.5 million (down 35.9% from $5.45 million in 2024) and raised full-year revenue guidance to $97–$98 million. Analysts highlighted improved gross margins and strategic focus on its core RNS business as key positives.
Revenue
, NeuroPace’s revenue growth outpaced expectations. DIXI product sales, however, declined as the company winds down the line. The ’s strong performance reflects expanding adoption across geographies and Level 4 centers, with gross margins reaching 77.4%.
Earnings/Net Income
, a 42.1% improvement. , sustained losses over six years underscore ongoing financial challenges. The EPS improvement, coupled with positive adjusted EBITDA, signals operational discipline but highlights the need for continued cost management.
Post-Earnings Price Action Review

NeuroPace’s stock surged 11.61% in a single trading day, 28.13% for the week, . , , and strategic clarity. Analysts at Leerink and Cantor Fitzgerald upgraded price targets, . However, mixed earnings estimate revisions and a Zacks Rank #3 (Hold) suggest cautious market sentiment.
CEO Commentary
, , , . . The CEO expressed confidence in RNS’s long-term potential, .
Guidance
. , . , .
Additional News
Analyst Upgrades, . .
Regulatory Progress, .
Strategic Shifts, . .
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet